N. Anthony Coles - Dec 9, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
CEO and Chairperson, Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Dec 9, 2022
Transactions value $
-$1,158,300
Form type
4
Date filed
12/13/2022, 03:44 PM
Previous filing
Sep 8, 2022
Next filing
Dec 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $175K +50K +1849.11% $3.50* 52.7K Dec 9, 2022 Direct F1, F2
transaction CERE Common Stock Sale -$1.19M -44.9K -85.11% $26.62 7.85K Dec 9, 2022 Direct F1, F3
transaction CERE Common Stock Sale -$139K -5.15K -65.55% $27.09 2.7K Dec 9, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -50K -1.61% $0.00 3.05M Dec 9, 2022 Common Stock 50K $3.50 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person.
F2 Includes 2,704 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021 and June 30, 2022.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.04 - $27.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 - $27.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter.